Romatoid Artrit Tedavisinde Kullanılan Janus Kinaz inhibitörü Tofasitinibin Serum Amiloid A ve IL-6 üzerine etkisi
Clinical and Experimental Immunology doi.10.1111/cei.12234
Tofacitinib is a JAK inhibitor currently approved for the treatment of RA in some parts of the world. In this paper, Migita et al tested the effects of tofacitinib on circulating serum amyloid A (SAA). SAA is a major acute-phase reactant in RA and studies have shown it may be a better marker for the assessment of inflammatory joint disease compared with C-reactive protein. SAA is induced by the binding of IL-6 and the activation of the JAK/STAT pathway, which is inhibited by tofacitinib. Results...